Registration Dossier

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
other: Weight of evidence
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)

Data source

Reference
Reference Type:
other: Weight of evidence
Title:
Toxicokinetics
Author:
Sustainability Support Services (Europe) AB
Year:
2012
Bibliographic source:
Based on the weight of evidence of various phys chem and bioaccumulative parameters in the dossier

Materials and methods

Objective of study:
toxicokinetics
Test guideline
Qualifier:
no guideline available
Principles of method if other than guideline:
Based on the weight of evidence of various phys chem and bioaccumulative parameters in the dossier
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Piperazine adipate
EC Number:
205-569-0
EC Name:
Piperazine adipate
Cas Number:
142-88-1
Molecular formula:
C6H10O4.C4H10N2
IUPAC Name:
piperazine adipate

Test animals

Species:
other: unspecified
Strain:
not specified
Sex:
not specified

Administration / exposure

Route of administration:
other: estimation
Vehicle:
unchanged (no vehicle)

Results and discussion

Toxicokinetic / pharmacokinetic studies

Details on absorption:
In toxico-kinetics, the fastest route of absorption is inhalation. The vapour pressure of piperazine adipate is equivalent to 280 Pascal at 25oC. Therefore it is assumed that absoprtion of piperazine adipate shall be moderate by the inhalation route. Assuming that the absoprtion via the other route of exposure (oral or dermal) is also significant but since the bio-concentration factor (BCF) of piperazine adipate is 3.162 which is below the threhold of 1000 when chemicals tend to bio-accumulate, even if piperazine adipate is absorbed it shall not bio-accumulate and thereby bio-concentration within the living system.

Details on distribution in tissues:
The water solubility of piperazine adipate is more compared to its solubility in organic solvent. Hence piperazine adipate shall not be distributed so easily to various parts of the body thru blood though there could be some distribution; given its solubility in the lipid fraction of blood. However, the low BCF will ensure that the chemical shall not bio-accumulate.
Details on excretion:
Since piperazine adipate is not likely to bio-accumulate inside the living system, it shall be excreted, either through the urine or the feaces.

Metabolite characterisation studies

Metabolites identified:
no

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): other: No bio-accumulation potential deduced on the basis of physico-chemical properties and bio-concentration factor
Based upon the physico-chemical properties and BCF of piperazine adipate, it has been deduced that the chemical has potentially low bio-accumulative property and hence shall be eliminated from the body system through urine or feaces.
Executive summary:

Based upon the physico-chemical properties and BCF of piperazine adipate, it has been deduced that the chemical has potentially low bio-accumulative property and hence shall be eliminated from the body system through urine or feaces.